Literature DB >> 18359170

Tumor location, interval between surgery and radiotherapy, and boost technique influence local control after breast-conserving surgery and radiation: retrospective analysis of monoinstitutional long-term results.

Hellen Knauerhase1, Manfred Strietzel, Bernd Gerber, Toralf Reimer, Rainer Fietkau.   

Abstract

PURPOSE: To obtain long-term data on local tumor control after treatment of invasive breast cancer by breast-conserving surgery and adjuvant radiotherapy (RT), in consideration of the interstitial high-dose-rate boost technique. PATIENTS AND METHODS: A total of 263 women with 268 mammary carcinomas (International Union Against Cancer Stage I-IIB) who had undergone breast-conserving surgery and adjuvant RT between 1990 and 1994 were included. The potential risk factors for local recurrence-free survival were investigated.
RESULTS: During a median follow-up period of 94 months, 27 locoregional recurrences, 25 of which were in breast, were diagnosed. The cumulative rate of in-breast recurrence was 4.1% +/- 1.4% at 5 years of follow-up and 9.9% +/- 2.4% at 10 years. The multivariate analysis identified medial tumor location and delayed RT (defined as an interval of >2 months between surgery and the start of RT) as significant risk factors for in-breast recurrence in the overall study population. Medial tumor location vs. lateral/central location (hazard ratio, 2.48; 95% confidence interval, 1.06-5.84) resulted in a cumulative in-breast recurrence rate of 22.5% +/- 8.3% vs. 6.9% +/- 2.3% at 10 years. Delayed RT (hazard ratio, 2.84; 95% confidence interval, 1.13-7.13) resulted in a cumulative in-breast recurrence rate of 18.5% +/- 6.2% vs. 6.8% +/- 2.4% at 10 years. The multivariate analysis also showed that the risk of in-breast recurrence was lower after high-dose-rate boost therapy than after external beam boost therapy in patients with laterally/centrally located tumors (hazard ratio, 3.25; 95% confidence interval, 0.91-11.65).
CONCLUSION: Tumor location, interval between surgery and RT, and boost technique might influence local control of breast cancer treated by breast-conserving surgery and RT.

Entities:  

Mesh:

Year:  2008        PMID: 18359170     DOI: 10.1016/j.ijrobp.2008.02.007

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  12 in total

1.  Ten-year results of a phase II study with a single fraction of high-dose-rate brachytherapy (FAST-boost) after whole breast irradiation in invasive breast carcinoma.

Authors:  José Luis Guinot; M Isabel Tortajada; María Carrascosa; Vicente Crispín; Ana Otero; Belén Ríos; Eleonor Rivin; Miguel Santos; Pablo Soler; Leoncio Arribas
Journal:  Clin Transl Oncol       Date:  2012-02       Impact factor: 3.405

Review 2.  Breast Reconstruction Following Cancer Treatment.

Authors:  Bernd Gerber; Mario Marx; Michael Untch; Andree Faridi
Journal:  Dtsch Arztebl Int       Date:  2015-08-31       Impact factor: 5.594

3.  Early-stage breast cancer conservative treatment: high-dose-rate brachytherapy boost in a single fraction of 700 cGy to the tumour bed.

Authors:  Aurora Rodríguez Pérez; Pilar María Samper Ots; María Concepción López Carrizosa; José Fermín Pérez-Regadera Gómez; José Zapatero Ortuño; Juan de Dios Sáez Garrido; Manuel Joaquín Martín de Miguel
Journal:  Clin Transl Oncol       Date:  2012-05       Impact factor: 3.405

4.  Delayed initiation of radiation therapy is associated with inferior outcomes for breast cancer patients with hormone receptor-negative tumors after breast-conserving surgery.

Authors:  Xiaoyan Ma; Jie Chen; Ding Ma; Yizhou Jiang; Zhebin Liu; Sheng Chen; Ying Zhang; Yizhou Shen; Xiaoli Yu; Zhaozhi Yang; Shuang Li; Miao Mo; Yongxiang Qian; Guangyu Liu; Jiong Wu; Zhiming Shao; Keda Yu; Genhong Di
Journal:  Gland Surg       Date:  2021-09

5.  Breast-Conserving Therapy Has Better Prognosis for Tumors in the Central and Nipple Portion of Breast Cancer Compared with Mastectomy: A SEER Data-Based Study.

Authors:  Jing Wang; Xiaoyu Wang; Zhenyu Zhong; Xue Li; Jiazheng Sun; Jie Li; Jiefeng Huang; Yunhai Li; Guosheng Ren; Hongzhong Li
Journal:  Front Oncol       Date:  2021-08-12       Impact factor: 6.244

Review 6.  Current status and perspectives of brachytherapy for breast cancer.

Authors:  Csaba Polgár; Tibor Major
Journal:  Int J Clin Oncol       Date:  2009-02-20       Impact factor: 3.402

7.  Medial tumor localization in breast cancer--an unappreciated risk factor?

Authors:  Elisabeth Bräutigam; Christine Track; Dietmar H Seewald; Johann Feichtinger; Kurt Spiegl; Josef Hammer
Journal:  Strahlenther Onkol       Date:  2009-10-06       Impact factor: 3.621

8.  The role of high-dose-rate brachytherapy boost in breast-conserving therapy: Long-term results of the Hungarian National Institute of Oncology.

Authors:  Csaba Polgár; Levente Jánváry; Tibor Major; András Somogyi; Zoltán Takácsi-Nagy; Georgina Fröhlich; János Fodor
Journal:  Rep Pract Oncol Radiother       Date:  2010-02-18

9.  Portfolio of prospective clinical trials including brachytherapy: an analysis of the ClinicalTrials.gov database.

Authors:  Nikola Cihoric; Alexandros Tsikkinis; Cristina Gutierrez Miguelez; Vratislav Strnad; Ivan Soldatovic; Pirus Ghadjar; Branislav Jeremic; Alan Dal Pra; Daniel M Aebersold; Kristina Lössl
Journal:  Radiat Oncol       Date:  2016-03-22       Impact factor: 3.481

10.  Waiting time for radiation therapy after breast-conserving surgery in early breast cancer: a retrospective analysis of local relapse and distant metastases in 615 patients.

Authors:  Raffaella Caponio; Maria Paola Ciliberti; Giusi Graziano; Rocco Necchia; Giovanni Scognamillo; Antonio Pascali; Sabino Bonaduce; Anna Milella; Gabriele Matichecchia; Cristian Cristofaro; Davide Di Fatta; Pasquale Tamborra; Marco Lioce
Journal:  Eur J Med Res       Date:  2016-08-11       Impact factor: 2.175

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.